Related Experiment Video
Updated: Dec 1, 2025

Models of Bone Metastasis
Published on: September 4, 2012
Pharmacologic management of metastatic bone disease
Eric Schwartz1, Zachery Reichert1, Catherine Van Poznak1
1Michigan Medicine: Rogel Cancer Center, United States of America.
Abstract:
Bone is a common site of metastases, particularly in advanced breast and prostate cancer. Skeletal related events associated with bone metastases include pathologic fracture, need for surgery/radiation to bone and cord compression. These events cause significant morbidity and mortality. Bisphosphonates as well as denosumab act on the bone microenvironment and reduce the rate of skeletal related events by approximately 25%-40%. Hence, these therapies are an important adjunctive therapy in cancer care. Despite the established efficacy and recommendations for their use in many international guidelines, these bone modifying agents are underutilized. This review examines the currently available guidelines on bone modifying agents in metastatic bone disease and summarizes their efficacy, risk and comparative benefits.
More Related Videos
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Bone Remodeling
Targeted Cancer Therapies
There are several types of targeted therapies against...
Urinary Tract Calculi V: Nursing Management

